Innate Lead Candidate Fails In Head And Neck Cancer But Partner AZ Offers Hope In NSCLC
Executive Summary
Innate’s lead candidate has reached the end of the road in head and neck carcinoma after a disappointing interim Phase III trial analysis but hope remains that a combination with partner AstraZeneca's Imfinzi could succeed elsewhere.
You may also be interested in...
Takeda Adds To Its Celiac Pipeline With Innate-Discovered Antibodies
Deal Snapshot: Using antibodies against an undisclosed target discovered and engineered by Innate, Takeda plans to investigate the potential of antibody-drug conjugates in celiac disease
Lacutamab Data Boost Prospects For Innate Pharma
The French biotech has presented positive Phase II data on lacutamab in mycosis fungoides at the EORTC-CLTG meeting in Madrid which looks to have de-risked the asset.
AstraZeneca’s Susan Galbraith On What’s Next In The Cancer Pipeline
One of the architects of AstraZeneca’s burgeoning cancer portfolio, oncology R&D head Susan Galbraith is making sure the firm does not rest on its laurels. She talked to Scrip about what’s coming next from the UK major’s cancer pipeline.